Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel

Selatogrel is a potent and selective reversible P2Y12 receptor antagonist in development for early treatment of acute myocardial infarction via subcutaneous (s.c.) self‐injection. Selatogrel is almost exclusively eliminated via the hepatobiliary route. Hepatic impairment is associated with reduced d...

Descripción completa

Detalles Bibliográficos
Autores principales: Schilling, Uta, Hsin, Chih‐Hsuan, Delahaye, Stephane, Krause, Andreas, Wuelfrath, Hauke, Halabi, Atef, Dingemanse, Jasper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372424/
https://www.ncbi.nlm.nih.gov/pubmed/35583936
http://dx.doi.org/10.1111/cts.13298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372424/
https://www.ncbi.nlm.nih.gov/pubmed/35583936
http://dx.doi.org/10.1111/cts.13298

Ejemplares similares